Today, we announced our Q4 and full-year 2024 financial results and highlighted our recent business progress including: - our filing of a U.S. IND for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor and - a progress update on our RAMP 205 trial in first-line metastatic pancreatic cancer Learn more: https://lnkd.in/erQ5EScY #VerastemOnc #cancerresearch #LGSOC #G12D #pancreaticcancer
